Financials

Discussions Technicals Seasonals

NXGN fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Nextgen Biomed Ltd. operates as a research and development company. Its primary product is Eyepen, a smart and modular device consisting of pens for injecting insulin, and helps users self-manage the treatment of diabetes by documenting the times and doses of taking insulin by injection. The company was founded on December 26, 1990 and is headquartered in Raanana, Israel.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

NXGN does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company